Recalcitrant Lichen Planopilaris Treated with Upadacitinib: A Case Series

This case series explores the treatment of recalcitrant lichen planopilaris (LPP) with upadacitinib, a Janus kinase (JAK) inhibitor. The study, conducted by the Department of Dermatology at La Fe University and Polytechnic Hospital in Valencia, Spain, presents evidence that upadacitinib may be an effective treatment option for patients with LPP who have not responded to other therapies. The authors report positive outcomes in the cases treated, suggesting that JAK inhibitors could play a significant role in managing this challenging condition. No conflicts of interest or funding sources were reported.